Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 9
1966 5
1967 8
1968 4
1969 5
1970 5
1971 17
1972 11
1973 18
1974 13
1975 8
1976 21
1977 11
1978 10
1979 12
1980 13
1981 10
1982 12
1983 11
1984 5
1985 7
1986 4
1987 6
1988 7
1989 6
1990 4
1991 2
1992 2
1993 4
1994 4
1995 3
1996 7
1997 8
1998 6
1999 7
2000 9
2001 6
2002 8
2003 5
2004 5
2005 7
2006 7
2007 5
2008 8
2009 5
2010 5
2011 14
2012 7
2013 5
2014 6
2015 11
2016 8
2017 7
2018 4
2019 3
2020 8
2021 4
2022 5
2023 1
2024 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

431 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Botulinum Toxin A for the Management of Melasma: A Split-Face, Randomized Control Study.
Chaijaras S, Boonpethkaew S, Chirasuthat S, Sakpuwadol N, Yongpisarn T, Anansiripun P, Vachiramon V. Chaijaras S, et al. J Cosmet Dermatol. 2025 Aug;24(8):e70376. doi: 10.1111/jocd.70376. J Cosmet Dermatol. 2025. PMID: 40747795 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the effectiveness of adjunctive incoBoNT-A injection combined with triple combination cream (TCC, 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide) for treating and preventing melasma recurrence compared to topical therapy al …
OBJECTIVE: To evaluate the effectiveness of adjunctive incoBoNT-A injection combined with triple combination cream (TCC, 4% hydroquinone, 0. …
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Kempen JH, Altaweel MM, Drye LT, Holbrook JT, Jabs DA, Sugar EA, Thorne JE. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2015 Oct;122(10):1967-75. doi: 10.1016/j.ophtha.2015.06.042. Epub 2015 Aug 20. Ophthalmology. 2015. PMID: 26298715 Free PMC article. Clinical Trial.
PURPOSE: To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis. ...Although macular edema improved sig …
PURPOSE: To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented …
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Chu L, Acosta AM, Aazami H, Dennis P, De Valle O, Ehmer D Jr, Hedrick JA, Ansley JF. Chu L, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2221699. doi: 10.1001/jamanetworkopen.2022.21699. JAMA Netw Open. 2022. PMID: 35834251 Free PMC article. Clinical Trial.
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin, 0.3%, or fluocinolone acetonide, 0.025%, otic solution alone. OBJEC …
IMPORTANCE: Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treati …
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Ophthalmology. 2015 Oct;122(10):1976-86. doi: 10.1016/j.ophtha.2015.06.043. Epub 2015 Aug 19. Ophthalmology. 2015. PMID: 26298718 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the risks and quality-of-life (QoL) outcomes of fluocinolone acetonide implant versus systemic therapy with corticosteroid and immunosuppression when indicated for intermediate uveitis, posterior uveitis, and panuveitis. ...CONCLUSIONS: These re …
PURPOSE: To evaluate the risks and quality-of-life (QoL) outcomes of fluocinolone acetonide implant versus systemic therapy wi …
Efficacy and Safety of Generic Fluocinolone Acetonide, Hydroquinone, and Tretinoin Cream Compared With TRI-LUMA for the Treatment of Moderate-To-Severe Melasma in Chinese Patients: A Randomized, Single-Center, Placebo-Controlled Trial.
Hu H, Zhou P, Yao H, Zhu C, Shen B, Feng B, Yu X, Liu L. Hu H, et al. J Cosmet Dermatol. 2025 May;24(5):e70205. doi: 10.1111/jocd.70205. J Cosmet Dermatol. 2025. PMID: 40296512 Free PMC article. Clinical Trial.
BACKGROUND: Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however, the effects of this treatment in the Chinese population remain unclear. ...AIM: To evaluate the efficacy and safety of fluocinolone …
BACKGROUND: Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however …
Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
Holbrook JT, Sugar EA, Burke AE, Vitale AT, Thorne JE, Davis JL, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Holbrook JT, et al. Am J Ophthalmol. 2016 Apr;164:29-36. doi: 10.1016/j.ajo.2015.12.028. Epub 2015 Dec 31. Am J Ophthalmol. 2016. PMID: 26748056 Free PMC article. Clinical Trial.
PURPOSE: To describe fluocinolone acetonide implant dissociations in the Multicenter Uveitis Steroid Treatment (MUST) Trial. ...
PURPOSE: To describe fluocinolone acetonide implant dissociations in the Multicenter Uveitis Steroid Treatment (MUST) Trial. . …
Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Sugar EA, Holbrook JT, Kempen JH, Burke AE, Drye LT, Thorne JE, Louis TA, Jabs DA, Altaweel MM, Frick KD. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2014 Oct;121(10):1855-62. doi: 10.1016/j.ophtha.2014.04.022. Epub 2014 Jun 5. Ophthalmology. 2014. PMID: 24908205 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate the 3-year incremental cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for the treatment of noninfectious intermediate, posterior, and panuveitis. ...The probability of the ICER being cost-effective at thresholds o …
OBJECTIVE: To evaluate the 3-year incremental cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for …
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group; Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, et al. Ophthalmology. 2011 Oct;118(10):1916-26. doi: 10.1016/j.ophtha.2011.07.027. Epub 2011 Aug 15. Ophthalmology. 2011. PMID: 21840602 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus fluocinolone acetonide implant (implant therapy) for noninfectious intermediate, posterior, or panuveitis (uveitis). ...
OBJECTIVE: To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus …
Pharmacokinetics of ciprofloxacin and fluocinolone acetonide otic solution in pediatric patients.
Spektor Z, Hussain I, Van Leeuwen RN, Goudy S, Esterhuizen K, Meyer R, Hedrick J. Spektor Z, et al. Am J Otolaryngol. 2022 Sep-Oct;43(5):103573. doi: 10.1016/j.amjoto.2022.103573. Epub 2022 Aug 5. Am J Otolaryngol. 2022. PMID: 35988360 Free article. Clinical Trial.
Blood samples were analyzed to detect ciprofloxacin and fluocinolone acetonide concentrations using two validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) methods, with the lower limit of quantification for ciprofloxacin and fluocinolone a …
Blood samples were analyzed to detect ciprofloxacin and fluocinolone acetonide concentrations using two validated liquid chrom …
Incidence and Outcome of Uveitic Glaucoma in Eyes With Intermediate, Posterior, or Panuveitis Followed up to 10 Years After Randomization to Fluocinolone Acetonide Implant or Systemic Therapy.
Kempen JH, Van Natta ML, Friedman DS, Altaweel MM, Ansari H, Dunn JP, Elner SG, Holbrook JT, Lim LL, Sugar EA, Jabs DA; Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Kempen JH, et al. Am J Ophthalmol. 2020 Nov;219:303-316. doi: 10.1016/j.ajo.2020.06.038. Epub 2020 Jul 3. Am J Ophthalmol. 2020. PMID: 32628922 Free PMC article. Clinical Trial.
PURPOSE: To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or fluocinolone acetonide (0.59 mg, "implant") therapy. DESIGN: Prospective Follow-up of the Multicenter Uveitis Steroid Treatment …
PURPOSE: To evaluate long-term risk and outcomes of glaucoma in eyes with intermediate, posterior, and panuveitis managed with systemic or …
431 results